Table 1. Overview of radiological criteria in immuno-oncology.

Variables	RECIST1.1 (15)	irRC (13)	irRECIST (16)	iRECIST (12)	imRECIST (17)
Lesion measurement	Unidimensional	Bidimensional	Unidimensional	Unidimensional	Unidimensional
Measurable lesion size (CT) (mm)	≥10	5×5	≥10	≥10	≥10
Baseline lesion number	5 in total, 2 per organ	10 in total, 5 per organ	5 in total, 2 per organ	5 in total, 2 per organ	5 in total, 2 per organ
CR	All lesions disappeared	All lesions disappeared	All lesions disappeared	All lesions disappeared	All lesions disappeared
PR	Decline ≥30% from baseline	Decline ≥50% from baseline	Decline ≥30% from baseline	Decline ≥30% from baseline	Decline ≥30% from baseline
SD	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD
PD	≥20% increase from nadir (≥5 mm); appearance of new lesions	≥25% increase from nadir	≥20% increase from nadir	≥20% increase from nadir	≥20% increase from nadir
PD-confirmed	No applicable	≥4 weeks	4 to 12 weeks	4 to 8 weeks	≥4 weeks

RECIST, Response Evaluation Criteria in Solid Tumors; irRC, immune-related response criteria; iRECIST, immune RECIST; irRECIST, immune-related RECIST; imRECIST, immune-modified RECIST; CT, computed tomography; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.